GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution

Gene Therapy

Volumn 19, Issue 11, 2012, Pages 1048-1057

  Guedan, S ^a,b   Grases, D ^a   Rojas, J J ^a   Gros, A ^a   Vilardell, F ^c   Vile, R ^d   Mercade, E ^b   Cascallo, M ^a   Alemany, R ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^d MAYO CLINIC   (United States)

Author keywords

Antitumor efficacy; Fusogenic membrane glycoproteins; Oncolytic adenovirus; Syncytia; Viral spread

Indexed keywords

ADENOVIRUS VECTOR; ICOVIR15; ICOVIR16; ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL FUSION; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; GIBBON LEUKEMIA VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SYNCYTIUM; TREATMENT OUTCOME; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS ENVELOPE; VIRUS GENOME;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CRICETINAE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; GIANT CELLS; HUMANS; INJECTIONS; LEUKEMIA VIRUS, GIBBON APE; MALE; MICE; NEOPLASMS; ONCOLYTIC VIRUSES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; GIBBON APE LEUKEMIA VIRUS; MUS;

EID: 84869082908     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.184     Document Type: Article

References (42)

1. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000; 18: 723-727. (Pubitemid 30460686)
2. Aghi M, Martuza RL. Oncolytic viral therapies - the clinical experience. Oncogene 2005; 24: 7802-7816. (Pubitemid 41670681)
3. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010; 18: 251-263.
4. Gros A, Guedan S. Adenovirus release from the infected cell as a key factor for adenovirus oncolysis. Open Gene Ther J 2010; 3: 24-30.
5. Chu RL, Post DE, Khuri FR, Van Meir EG. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004; 10: 5299-5312. (Pubitemid 39100464)
6. Gros A, Puig C, Guedan S, Rojas JJ, Alemany R, Cascallo M. Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Mol Ther 2010; 18: 903-911.
7. Homicsko K, Lukashev A, Iggo RD. RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer. Cancer Res 2005; 65: 6882-6890. (Pubitemid 41060727)
8. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF et al. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 2008; 16: 487-493. (Pubitemid 351314987)
9. Cody JJ, Douglas JT. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009; 16: 473-488.
10. Ganesh S, Gonzalez Edick M, Idamakanti N, Abramova M, Vanroey M, Robinson M et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res 2007; 67: 4399-4407. (Pubitemid 46815089)
11. Kim JH, Lee YS, Kim H, Huang JH, Yoon AR, Yun CO. Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. J Natl Cancer Inst 2006; 98: 1482-1493. (Pubitemid 44605593)
12. Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R. Hyaluronidase Expression by an Oncolytic Adenovirus Enhances Its Intratumoral Spread and Suppresses Tumor Growth. Mol Ther 2010; 18: 1275-1283.
13. Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L et al. In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 2003; 7: 755-764. (Pubitemid 36790252)
14. Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12: 5859-5868. (Pubitemid 44629619)
15. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z et al. Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. Cancer Res 2007; 67: 6872-6881. (Pubitemid 47105534)
16. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034-14039. (Pubitemid 41377698)
17. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res 1999; 59: 410-413. (Pubitemid 29048876)
18. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol Ther 2000; 1: 56-62.
19. Cascante A, Abate-Daga D, Garcia-Rodriguez L, Gonzalez JR, Alemany R, Fillat C. GCV modulates the antitumoural efficacy of a replicative adenovirus expressing the Tat8-TK as a late gene in a pancreatic tumour model. Gene Therapy 2007; 14: 1471-1480. (Pubitemid 47500650)
20. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 2000; 60: 1492-1497. (Pubitemid 30183412)
21. Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 2002; 62: 6566-6578. (Pubitemid 35364123)
22. Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M et al. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Therapy 2006; 13: 138 -149. (Pubitemid 43039906)
23. Ebert O, Shinozaki K, Kournioti C, Park MS, Garcia-Sastre A, Woo SL. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res 2004; 64: 3265-3270. (Pubitemid 38581431)
24. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Mol Ther 2003; 7: 748-754. (Pubitemid 36790251)
25. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006; 66: 4835-4842.
26. Li H, Haviv YS, Derdeyn CA, Lam J, Coolidge C, Hunter E et al. Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Hum Gene Ther 2001; 12: 2155-2165. (Pubitemid 34075181)
27. Ahmed A, Jevremovic D, Suzuki K, Kottke T, Thompson J, Emery S et al. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy. Gene Therapy 2003; 10: 1663-1671. (Pubitemid 37069494)
28. Guedan S, Gros A, Cascallo M, Vile R, Mercade E, Alemany R. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication. Gene Therapy 2008; 15: 1240-1245.
29. Rojas JJ, Guedan S, Searle PF, Martinez-Quintanilla J, Gil-Hoyos R, Alcayaga-Miranda F et al. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Mol Ther 2010; 18: 1960-1971.
30. Gros A, Martinez-Quintanilla J, Puig C, Guedan S, Mollevi DG, Alemany R et al. Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. Cancer Res 2008; 68: 8928-8937.
31. Linardakis E, Bateman A, Phan V, Ahmed A, Gough M, Olivier K et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res 2002; 62: 5495-5504.
32. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276. (Pubitemid 43259903)
33. Bortolanza S, Alzuguren P, Bunuales M, Qian C, Prieto J, Hernandez-Alcoceba R. Human adenovirus replicates in immunocompetent models of pancreatic cancer in Syrian hamsters. Hum Gene Ther 2007; 18: 681-690. (Pubitemid 47378065)
34. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921. (Pubitemid 23277501)
35. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 2007; 15: 1607-1615. (Pubitemid 47296599)
36. Bridge E, Ketner G. Redundant control of adenovirus late gene expression by early region 4. J Virol 1989; 63: 631-638. (Pubitemid 19057228)
37. Suzuki K, Alemany R, Yamamoto M, Curiel DT. The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 2002; 8: 3348-3359. (Pubitemid 35340708)
38. Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 2003; 21: 1328-1335. (Pubitemid 37356618)
39. Edwards SJ, Dix BR, Myers CJ, Dobson-Le D, Huschtscha L, Hibma M et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 2002; 76: 12483-12490. (Pubitemid 35386934)
40. Villanueva A, Garcia C, Paules AB, Vicente M, Megias M, Reyes G et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 1998; 17: 1969-1978. (Pubitemid 28488465)
41. Cotten M, Saltik M, Kursa M, Wagner E, Maass G, Birnstiel ML. Psoralen treatment of adenovirus particles eliminates virus replication and transcription while maintaining the endosomolytic activity of the virus capsid. Virology 1994; 205: 254-261. (Pubitemid 24360612)
42. Cascallo M, Gros A, Bayo N, Serrano T, Capella G, Alemany R. Deletion of VAI and VAII RNA genes in the design of oncolytic adenoviruses. Hum Gene Ther 2006; 17: 929-940. (Pubitemid 46076753)